MOTS-C
MOTS-c • Also called MOTS C
MOTS-C is marketed for metabolic resilience and longevity, but it sits in the same restricted cluster as many performance peptides.
Current status
Restricted
Metabolic-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Longevity clinics continue to watch for any formal policy movement.
Primary Use
Metabolic-related interest
Also searched as
MOTS C
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 29, 2023
Current status signal recorded: Longevity-focused peptide access remains constrained by Category 2 treatment..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when MOTS-C status changes
State-specific notes
Florida
Clinic marketing outpaces compliant availability.